Cytek Biosciences (CTKB) Cash from Operations Growth (1y) (2021 - 2026)
Cytek Biosciences (CTKB) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn | 21.54% |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn | 13.50% |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn | 14.62% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 124.64% |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn | -11.16% |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn | 78.72% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | -0.23% |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn | -12.60% |
| 10 | Cytek Biosciences | 609.76 Mn | 535.91 Mn | 28.34 Mn | 1,165.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,165.74% |
| Mar 31, 2026 | -2,088.80% |
| Dec 31, 2025 | -138.61% |
| Sep 30, 2025 | -129.48% |
| Jun 30, 2025 | -98.26% |
| Mar 31, 2025 | -103.16% |
| Dec 31, 2024 | -79.01% |
| Sep 30, 2024 | 411.89% |
| Jun 30, 2024 | 317.68% |
| Mar 31, 2024 | 38.45% |
| Dec 31, 2023 | 53.59% |
| Sep 30, 2023 | 43.51% |
| Jun 30, 2023 | 69.81% |
| Mar 31, 2023 | 293.11% |
| Dec 31, 2022 | 13.67% |
| Sep 30, 2022 | -746.34% |
| Jun 30, 2022 | -141.19% |
| Mar 31, 2022 | -176.49% |
| Dec 31, 2021 | -53.20% |
| Sep 30, 2021 | -47.01% |